



State of Louisiana
Louisiana Department of Health
Office of the Secretary

VIA ELECTRONIC MAIL ONLY

October 16, 2019

Bill Brooks
Associate Regional Administrator
Division of Medicaid & Children's Health
DHHS/Centers for Medicare and Medicaid Services
1301 Young Street, Room #833
Dallas, Texas 75202

RE: Louisiana Title XIX State Plan
Transmittal No. 19-0028

Dear Mr. Brooks:

I have reviewed and approved the enclosed Louisiana Title XIX State Plan material.

I recommend this material for adoption and inclusion in the body of the State Plan. Should you have any questions or concerns regarding this matter, please contact Karen Barnes at (225) 342-3881 or via email at Karen.Barnes@la.gov.

Warmly,

By: Cindy Ruse, for
Rebekah E. Gee MD, MPH
Secretary

Attachments (2)

REG:JS:MVJ

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL FOR: CENTERS FOR MEDICARE & MEDICAID SERVICES	1. TRANSMITTAL NUMBER 19-0028	2. STATE Louisiana
	3. PROGRAM IDENTIFICATION: TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)	
TO: REGIONAL ADMINISTRATOR CENTERS FOR MEDICARE & MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES		4. PROPOSED EFFECTIVE DATE October 1, 2019

5. TYPE OF PLAN MATERIAL (Check One)
 NEW STATE PLAN AMENDMENT TO BE CONSIDERED AS NEW PLAN AMENDMENT

COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMENDMENT (Separate transmittal for each amendment)


6. FEDERAL STATUTE/REGULATION CITATION Section 1004 of the SUPPORT for Patients and Communities Act	7. FEDERAL BUDGET IMPACT a. FFY 2020 \$0 b. FFY 2021 \$0
---	--

8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT Section 4.26, Pages 74d and 74e	9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable) None – new pages
--	--

10. SUBJECT OF AMENDMENT: **The purpose of this SPA is to implement Medicaid drug utilization review (DUR) provisions that, in compliance with the SUPPORT for Patients and Communities Act, are designed to reduce opioid-related fraud, misuse and abuse.**

11. GOVERNOR'S REVIEW (Check One)

GOVERNOR'S OFFICE REPORTED NO COMMENT OTHER, AS SPECIFIED
 COMMENTS OF GOVERNOR'S OFFICE ENCLOSED The Governor does not review State Plan material.
 NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL

12. SIGNATURE OF STATE AGENCY OFFICIAL 	16. RETURN TO Jen Steele, Medicaid Director State of Louisiana Department of Health 628 North 4th Street P.O. Box 91030 Baton Rouge, LA 70821-9030
13. TYPED NAME Cindy Rives, designee for Rebekah E. Gee MD, MPH	
14. TITLE Secretary	
15. DATE SUBMITTED October 16, 2019	

FOR REGIONAL OFFICE USE ONLY

17. DATE RECEIVED	18. DATE APPROVED
-------------------	-------------------

PLAN APPROVED - ONE COPY ATTACHED

19. EFFECTIVE DATE OF APPROVED MATERIAL	20. SIGNATURE OF REGIONAL OFFICIAL
21. TYPED NAME	22. TITLE

23. REMARKS

Revision: HCFA-PM (MB)

State/Territory: LOUISIANA**Citation**

Section 1004 of the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act

Drug Utilization Review Requirements to Comply with the SUPPORT for Patients and Communities Act**1. Claims Review Limitations**

The State has opioid-related prospective point of sale (POS) safety edits and retrospective reviews in place to address:

- a. Duplicate fill and early fill alerts;
- b. Quantity limits;
- c. Morphine milligram equivalent (MME) limits; and
- d. Therapeutic duplication edits for:
 - i. Opioids/benzodiazepines
 - ii. Short-acting opioids/short-acting opioids
 - iii. Long-acting opioids/long-acting opioids

The State has the following annual retrospective utilization reviews for opioid safety:

- a. Concurrent opioid with benzodiazepines;
- b. Concurrent opioid with sleep agents;
- c. Concurrent opioid with antipsychotic agents; and
- d. Fentanyl transdermal, focus on Centers for Disease Control and Prevention (CDC) Guideline.

2. Program to Monitor Antipsychotic Medications by Children

The State has therapeutic duplication edits for oral/oral antipsychotic agents and injectable/injectable antipsychotic agents. Clinical authorization is required for antipsychotic medications prescribed for all children 0-5 years old. Antipsychotic medications have quantity limits and/or maximum doses and require a diagnosis code for all recipients. Pharmacy claims that exceed these limits will deny at POS. Overrides are addressed by the pharmacist after consultation with the prescriber or through the prior authorization process, depending on the edit.

The State performs annual retrospective utilization reviews for concurrent use of antipsychotic agents.

3. Fraud and Abuse Identification

Recipient profiles are reviewed based on pre-determined criteria. If potential misuse or over-utilization is identified, the recipient will be referred for pharmacy and/or prescriber lock-in.

4. Medicaid Managed Care Organizations Requirements

Effective October 1, 2019, the Louisiana MCO contracts were revised to comply with requirements of Section 1004 of the SUPPORT for Patients and Communities Act.